Liver Enzyme Elevation in Coronavirus Disease 2019: A Multicenter, Retrospective, Cross-Sectional Study
| العنوان: | Liver Enzyme Elevation in Coronavirus Disease 2019: A Multicenter, Retrospective, Cross-Sectional Study |
|---|---|
| المؤلفون: | Ying feng Lu, Cheng Yin Ye, Shan yan Zhang, Xi Jin, Chan yuan Ye, Jue qing Gu, Jianhua Hu, Xiaoyan Wang, Liang Yu, Hongyu Jia, Ting Bo Liang, Guo dong Yu, Xiaopeng Yu, Lin Zheng, Yun Qing Qiu, Jiang shan Lian, Shao rui Hao, Yi da Yang, Huan Cai, Yi Min Zhang, Xiaoli Zhang, Ji Fang Sheng, Ci liang Jin, Lanjuan Li, Dai Rong Xiang |
| المصدر: | The American Journal of Gastroenterology |
| بيانات النشر: | Wolters Kluwer, 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | Male, medicine.medical_specialty, Hepatitis, Viral, Human, Cross-sectional study, Pneumonia, Viral, Gastroenterology, Article, Betacoronavirus, 03 medical and health sciences, 0302 clinical medicine, Liver Function Tests, Risk Factors, Interquartile range, Internal medicine, Epidemiology, medicine, Humans, Pandemics, Retrospective Studies, Hepatitis, Hepatology, medicine.diagnostic_test, SARS-CoV-2, business.industry, Liver Diseases, COVID-19, Retrospective cohort study, Middle Aged, medicine.disease, Pneumonia, Diarrhea, Cross-Sectional Studies, Liver, 030220 oncology & carcinogenesis, Female, 030211 gastroenterology & hepatology, medicine.symptom, Coronavirus Infections, business, Liver function tests |
| الوصف: | Introduction Elevated liver enzyme levels are observed in patients with coronavirus disease 2019 (COVID-19); however, these features have not been characterized. Methods Hospitalized patients with COVID-19 in Zhejiang Province, China, from January 17 to February 12, 2020, were enrolled. Liver enzyme level elevation was defined as alanine aminotransferase level >35 U/L for men and 25 U/L for women at admission. Patients with normal alanine aminotransferase levels were included in the control group. Reverse transcription polymerase chain reaction was used to confirm severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, and patients symptomatic with SARS-CoV-2 infection were defined as patients with COVID-19. Epidemiological, demographic, clinical, laboratory, treatment, and outcome data were collected and compared. Results Of 788 patients with COVID-19, 222 (28.2%) patients had elevated liver enzyme levels (median [interquartile range {IQR}] age, 47.0 [35.0-55.0] years; 40.5% women). Being male, overweight, and smoking increased the risk of liver enzyme level elevation. The liver enzyme level elevation group had lesser pharyngalgia and more diarrhea than the control group. The median time from illness onset to admission was 3 days for liver enzyme level elevation groups (IQR, 2-6), whereas the median hospitalization time for 86 (38.7%) discharged patients was 13 days (IQR, 11-16). No differences in disease severity and clinical outcomes were noted between the groups. Discussion We found that 28.2% of patients with COVID-19 presented with elevated liver enzyme levels on admission, which could partially be related to SARS-CoV-2 infection. Male patients had a higher risk of liver enzyme level elevation. With early medical intervention, liver enzyme level elevation did not worsen the outcomes of patients with COVID-19. |
| اللغة: | English |
| تدمد: | 1572-0241 0002-9270 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8511228f707338e4a7745ffb8d2c84e8 http://europepmc.org/articles/PMC7288765 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....8511228f707338e4a7745ffb8d2c84e8 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15720241 00029270 |
|---|